This has led to detailed characterization of the involvement of GLP‐1 in physiological and pathophysiological mechanisms which underlie the use of GLP‐1R agonists as anti‐diabetic and anti‐obesity agents (Andersen et al., 2018). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.